ストックスクリーナーアプリを入手
39.63
7.49%
-3.21
前日終値:
$42.84
開ける：
$42.74
24時間の取引高:
290.57K
Relative Volume:
1.44
時価総額：
$790.63M
収益：
$925.00K
当期純損益:
$-98.64M
株価収益率:
-7.8958
EPS:
-5.0191
ネットキャッシュフロー:
$-83.37M
1週間 パフォーマンス:
+12.14%
1か月 パフォーマンス:
+41.49%
6か月 パフォーマンス:
+121.15%
1年 パフォーマンス:
+80.46%
1日の値動き範囲:
$38.18
$43.00
1週間の範囲:
$32.00
$43.66
52週間の値動き範囲:
$15.93
$43.66
Neurogene Inc Stock (NGNE) Company Profile
Compare NGNE vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
39.63 | 790.63M | 925.00K | -98.64M | -83.37M | -5.0191 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-17 | 開始されました | Craig Hallum | Buy |
| 2025-05-16 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-06-27 | 開始されました | BMO Capital Markets | Outperform |
| 2024-06-11 | 開始されました | Robert W. Baird | Outperform |
| 2024-04-29 | 開始されました | Leerink Partners | Outperform |
| 2024-03-21 | 開始されました | William Blair | Outperform |
| 2024-01-08 | 開始されました | H.C. Wainwright | Buy |
| 2024-01-05 | 開始されました | Stifel | Buy |
| 2024-01-04 | 開始されました | TD Cowen | Outperform |
すべてを表示
Neurogene Inc (NGNE) 最新ニュース
Neurogene Surges To A New 52-Week High: Will NGN-401 Reshape The Rett Syndrome Market? - RTTNews
Rett gene therapy drives lasting developmental gains: Long-term data - Rett Syndrome News
Neurogene president & CFO Cvijic sells $173,375 in stock - Investing.com
Insider Sell: Christine Cvijic Sells 4,800 Shares of Neurogene I - GuruFocus
Form 4 Neurogene Inc For: 7 July By Investing.com - Investing.com Nigeria
Neurogene (NGNE) CFO sells 4,800 shares and retains 84,040 including RSUs - Stock Titan
Neurogene president & CFO Cvijic sells $173,375 in stock By Investing.com - Investing.com Canada
A Quick Look at Today's Ratings for Neurogene(NGNE.US), With a Forecast Between $60 to $180 - Moomoo
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Neurogene lures 6 new hires with stock options tied to July 6 close - Stock Titan
Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $46 - Moomoo
Enterprise value to revenue forward of Neurogene Inc. – NASDAQ:NGNE - TradingView
Neurogene prices $125M equity offering - MSN
Neurogene announces pricing of $125 million public offering - The Pharma Letter
Neurogene president and CFO Cvijic sells $166,586 of company stock By Investing.com - Investing.com South Africa
Neurogene president and CFO Cvijic sells $166,586 of company stock - Investing.com
Form 4 Neurogene Inc For: 2 July By Investing.com - Investing.com Canada
Neurogene (NGNE) CFO’s 4,800-share sale under 10b5-1 plan - Stock Titan
Neurogene: 'Hold' EMBOLDEN Study Underway And 2nd Half 2027 Topline Data - Seeking Alpha
Form 424B5 Neurogene Inc For: 2 July By Investing.com - Investing.com Canada
Neurogene Nets ~$135 Million From Equity Offering; Underwriters Exercise Full Option - TradingView
Neurogene (NGNE) secures $134.8M, extending cash runway into 2029 - Stock Titan
Citizens reiterates Taysha Gene Therapies stock rating on therapy progress By Investing.com - Investing.com Canada
Citizens reiterates Taysha Gene Therapies stock rating on therapy progress - Investing.com
Leerink raises Neurogene stock price target to $77 on Rett data By Investing.com - Investing.com South Africa
Neurogene (NGNE) sells 3.5M shares, pre-funded warrants in $117M deal - Stock Titan
Leerink raises Neurogene stock price target to $77 on Rett data - Investing.com Nigeria
Neurogene Inc. Stock 12‑Month Price Target Raised to $79.62, Implies 153% Upside - TradingView
Neurogene prices $125 million public offering at $30 per share By Investing.com - Investing.com Australia
Neurogene prices $125 million public offering at $30 per share - Investing.com
Neurogene Sets Pricing For $125 Million Public Offering - TradingView
Why is Neurogene stock sliding today? By Investing.com - Investing.com Canada
Neurogene Prices $125 Million Public Offering - marketscreener.com
Neurogene locks in $125M stock sale, closing expected July 2 - Stock Titan
Neurogene Inc. (NGNE) Discusses Updated Phase 1/2 Data for NGN-401 Gene Therapy in Rett SyndromeSlideshow - Seeking Alpha
Neurogene prices $125M public offering at $30/share - scanx.trade
Form 424B5 Neurogene Inc For: 30 June - Investing.com UK
Neurogene launches public offering of common stock By Investing.com - Investing.com South Africa
Neurogene to Sell Shares in Secondary Offering - Moomoo
Form 424B5 Neurogene Inc For: 30 June By Investing.com - Investing.com Australia
Neurogene stock falls on public offering announcement By Investing.com - Investing.com India
Neurogene stock falls on public offering announcement - Investing.com UK
Neurogene launches public stock offering - MSN
Neurogene Inc Files For Offering Of Common Stock, Pre-Funded Warrants To Buy Common Stock Size Not DisclosedSEC Filing - TradingView
Neurogene Launches Public Offering - marketscreener.com
Neurogene Inc. (NGNE) files to offer common stock and pre-funded warrants - Stock Titan
Neurogene Inc (NGNE) 財務データ
収益
当期純利益
現金流量
EPS
Neurogene Inc (NGNE) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Cvijic Christine Mikail | President and CFO |
Jul 06 '26 |
Sale |
36.02 |
600 |
21,613 |
88,240 |
| Cvijic Christine Mikail | President and CFO |
Jul 02 '26 |
Sale |
34.82 |
4,061 |
141,417 |
88,840 |
| Cvijic Christine Mikail | President and CFO |
Jul 01 '26 |
Sale |
34.06 |
739 |
25,170 |
92,901 |
| Cvijic Christine Mikail | President and CFO |
May 06 '26 |
Sale |
31.25 |
9,600 |
300,043 |
93,640 |
2.64%
大文字化:
|
ボリューム (24 時間):